Garcia, Agustin A. published the artcilePhase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis, Formula: C20H17FO4S, the publication is Investigational New Drugs (2006), 24(1), 79-83, database is CAplus and MEDLINE.
Background: The objective of this phase I study was to determine the maximal tolerated dose (MTD) of the combination of weekly docetaxel and exisulind in patients with advanced solid tumors. Patients and methods: Patients with advanced or refractory solid tumors were treated with i.v. weekly docetaxel with daily oral exisulind. The following dose levels (docetaxel/exisulind) were explored: 30-mg/m2/200 mg po bid, 35/200, 35/250 and 40/250. Docetaxel was administered weekly for 6 wk followed by 2 wk off, and exisulind was taken twice daily. Each cycle was 8 wk. Results: Eighteen patients were enrolled in the study. All of them had received prior systemic therapy. Most patients had either melanoma or carcinomas of the upper gastrointestinal tract. A total of 31 cycles of therapy were administered. DLTs were grade 3 diarrhea, anorexia and fatigue and grade 3 cutaneous toxicity at dose level 4 (40/250). Myelosuppression was mild. Fatigue and gastrointestinal toxicity (anorexia, dyspepsia, nausea, abdominal pain and diarrhea) represented the most common toxicities. However, grade 3 and grade 4 toxicities were uncommon. There were no treatment related deaths. No objective responses were observed and five patients achieved stable disease. Conclusions: The recommended dose for phase II studies is weekly docetaxel 35 mg/m2 for 6 wk followed by 2 wk off in combination with oral exisulind 250 mg po bid. This combination is feasible and well-tolerated at these doses.
Investigational New Drugs published new progress about 59973-80-7. 59973-80-7 belongs to naphthyridine, auxiliary class Immunology/Inflammation,COX, name is Sulindac sulfone, and the molecular formula is C20H17FO4S, Formula: C20H17FO4S.
Referemce:
https://en.wikipedia.org/wiki/1,8-Naphthyridine,
1,8-Naphthyridine | C8H6N2 – PubChem